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Traditional antiviral vaccines have relied mostly on atten-
uated or chemically inactivated live viruses. However, the
potential problems related either to an incomplete inacti-
vation procedure or to the reversion of an attenuated vac-
cine strain result in growing concerns for their use in
human vaccination approaches.
Virus-like particles (VLPs) are based on the expression of
virus capsid proteins, which spontaneously assemble in
particles structurally similar to native virus particles, with-
out containing viral genetic material. Thus, VLPs represent
a non-replicating, non-infectious particulate antigen
delivery system able to present conformationally struc-
tured viral proteins to the immune system. We have devel-
oped a candidate HIV-1 vaccine model based on HIV-1
Pr55gag VLPs (HIV-VLPs), produced in a baculovirus
expression system and presenting a gp120 molecule from
a HIV-1 isolate of the clade A (HIV-VLPAs). HIV-VLPAs
induce in Balb/c mice systemic and mucosal neutralizing
antibodies as well as cytotoxic T lymphocytes, by intra-
peritoneal as well as intranasal administration. HIV-
VLPAs efficiently induce maturation and activation of
MDDCs which show an enhanced Th1- and Th2-specific
cytokine production. In addition, HIV-VLP-loaded
MDDCs are able to induce a primary and secondary
response in autologous human CD4+ T cells, in an ex vivo
immunization assay. The versatility of the presentation
system, together with the strong immunogenicity, make
the VLP approach a highly valuable tool for vaccination
strategies.
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